Abstract: Wind energy systems comprise a wind accelerator having a support assembly and an outer structure surrounding the support assembly. The wind accelerator has a front region and a rear region. The rear region is substantially wider than the front region, and the outer structure tapers from the rear region to the front region. One or more turbines are mounted on the support assembly at or near the rear region of the wind accelerator or at or near the widest point of the wind accelerator.

Abstract: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening.

Abstract: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening.

Abstract: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening.

Abstract: The present invention relates to combinations of compounds such as compounds of the xanthenone acetic acid class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and vascular endothelial growth factor binders, in particular the monoclonal antibody Avastin™ (bevacizumab). More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical formulations containing such combinations.

Abstract: The present invention relates to combinations of the xanthenone acetic acids class such as 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and EGFR signalling pathway inhibitors. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compositions containing such combinations.

Abstract: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening.

Abstract: The present invention relates to compositions, methods, and kits for modulating tumor proliferation using G-rich oligonucleotides and one or more chemotherapeutic agents.

Abstract: A network of secure servers, requiring no central entity to administer user identities or access permissions. Each autonomous server hosts a set of user accounts. Users may link to and access the accounts of all other users in the network. Resources in accounts are private, but users may grant each other partial permissions to them. Links and permissions are independent of the location of accounts, and are cryptographically authenticated. Users may migrate their account between servers without loosing accumulated permissions, or breaking links that others have to their account. The ability to grant permissions may be delegated to reflect complex organizational structures. A permission may be configured to unlock data in a multitude of accounts. The system will support applications that require secure information sharing across multiple organizational boundaries, and provides a distributed security model which is feasible to deploy as it is wholly administered by its users.

Abstract: A network of secure servers, requiring no central entity to administer user identities or access permissions. Each autonomous server hosts a set of user accounts. Users may link to and access the accounts of all other users in the network. Resources in accounts are private, but users may grant each other partial permissions to them. Links and permissions are independent of the location of accounts, and are cryptographically authenticated. Users may migrate their account between servers without loosing accumulated permissions, or breaking links that others have to their account. The ability to grant permissions may be delegated to reflect complex organizational structures. A permission may be configured to unlock data in a multitude of accounts. The system will support applications that require secure information sharing across multiple organizational boundaries, and provides a distributed security model which is feasible to deploy as it is wholly administered by its users.

Abstract: A method and apparatus provide for remote control, monitoring and/or servicing of heat-treatment equipment via wireless communications networks. Specifically, the method and apparatus can be used in pre and post-weld heat-treatment applications for steel pipes in a variety of industries, including, but not limited to, power plants, chemical and petrochemical plants and refineries. Importantly, the embodiment generates and manages all the documentation necessary to input and verify the specified heat-treatment process. It will produce and deliver to the customer the reports and certificates required by the applicable quality control standards, requirements and regulatory authorities.

Abstract: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use in post-surgical, trauma, or tissue engineering applications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell communication is desirable.

Abstract: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening.

Abstract: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening.

Abstract: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening.

Abstract: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening.

Abstract: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening.

Abstract: A therapeutic and/or cosmetic formulation comprising at least one anti-sense polynucleotide to a connexin protein together with a pharmaceutically acceptable carrier or vehicle is useful in site specific down regulation of connexin protein expression, particularly in reduction of neuronal cells death, wound healing, reduction of inflammation, decrease of scar formation and skin rejuvenation and thickening.

Abstract: Methods and apparatuses for processing microfeature workpiece samples are disclosed herein. An apparatus in accordance with one embodiment of the invention includes a support body, a first contact surface portion, a second contact surface portion, and a sample holder configured to releasably carry the microfeature workpiece sample. The sample holder can be movable relative to the support body between a first position and a second position, wherein the sample holder has a first orientation relative to the first and second contact surface portions when in the first position and a second orientation when in the second position. At least one of the first and second contact surface portions can also be movable relative to the support body. Accordingly, an operator can move the first and/or second contact surface portions to make minor adjustments to an angle at which material is removed from the workpiece, and can move the sample holder to make more substantial adjustments.

Abstract: A network of secure servers, requiring no central entity to administer user identities or access permissions. Each autonomous server hosts a set of user accounts. Users may link to and access the accounts of all other users in the network. Resources in accounts are private, but users may grant each other partial permissions to them. Links and permissions are independent of the location of accounts, and are cryptographically authenticated. Users may migrate their account between servers without loosing accumulated permissions, or breaking links that others have to their account. The ability to grant permissions may be delegated to reflect complex organizational structures. A permission may be configured to unlock data in a multitude of accounts. The system will support applications that require secure information sharing across multiple organizational boundaries, and provides a distributed security model which is feasible to deploy as it is wholly administered by its users.